GlassScriptPhysician profile
Marc S Robins
NPI 1780671453
$606.77
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Undersea and Hyperbaric Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $94.19 · 2021: $46.38 · 2022: $110 · 2023: $21.86 · 2024: $60.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sechrist Industries INC | $150.96 | 2022-2024 | |
| Kci USA, INC. | $117.45 | 2019-2021 | |
| Smith+Nephew, INC. | $111.36 | 2019-2021 | |
| Ovik Health, LLC | $53.11 | 2019 | |
| Medline Industries LP | $52.69 | 2019-2020 | |
| Aroa Biosurgery Incorporated | $41.55 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $24.87 | 2019 | |
| Osiris Therapeutics INC. | $19.09 | 2019 | |
| Tactile Systems Technology INC | $12.92 | 2019 | |
| Acell, INC. | $11.63 | 2019 | |
| Convatec INC. | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.